title: Progress in immunotherapy rituximab.
abstract: Rituximab is an anti-CD20 chimeric monoclonal antibody that has shown substantial activity. Since its discovery, rituximab has been used with great success in a variety of hematological malignancies. Its success in the management of aggressive lymphomas led to expansion of its use in other conditions such as stem cell transplantation, post-transplant lymphoproliferative disorder, and other non-malignant conditions where B cell activation is thought to be important, such as idiopathic thrombocytopenic purpura and rheumatoid arthritis. The side effects have been remarkably few, particularly, infection is not more common than with chemotherapy alone. This article reviews the structure, mechanism of action, and uses of rituximab as monotherapy or in combination with chemotherapy.
authors.affiliation: Department of Hematology and Oncology, Tripoli Medical Center, PO Box 83763, Tripoli, Libya. Manal_elhabbsh@yahoo.com
authors.forename: Manal M
authors.initials: MM
authors.lastname: El-Habbash
authors.forename: Abukris M
authors.initials: AM
authors.lastname: Alwindi
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D000069283:Rituximab; D033581:Stem Cell Transplantation
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab